BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 1326438)

  • 1. In vitro and in vivo interactions of nitrovasodilators and zaprinast, a cGMP-selective phosphodiesterase inhibitor.
    Merkel LA; Rivera LM; Perrone MH; Lappe RW
    Eur J Pharmacol; 1992 May; 216(1):29-35. PubMed ID: 1326438
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Zaprinast, but not dipyridamole, reverses hemodynamic tolerance to nitroglycerin in vivo.
    De Garavilla L; Pagani ED; Buchholz RA; Dundore R; Bode DC; Volberg ML; Jackson KN; Pratt P; Silver PJ
    Eur J Pharmacol; 1996 Oct; 313(1-2):89-96. PubMed ID: 8905333
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reversal of nitroglycerin tolerance in vitro by the cGMP-phosphodiesterase inhibitor zaprinast.
    Pagani ED; VanAller GS; O'Connor B; Silver PJ
    Eur J Pharmacol; 1993 Oct; 243(2):141-7. PubMed ID: 8276063
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phosphodiesterase isozyme inhibition and the potentiation by zaprinast of endothelium-derived relaxing factor and guanylate cyclase stimulating agents in vascular smooth muscle.
    Harris AL; Lemp BM; Bentley RG; Perrone MH; Hamel LT; Silver PJ
    J Pharmacol Exp Ther; 1989 May; 249(2):394-400. PubMed ID: 2566675
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reversal or nitroglycerin tolerance by the cGMP phosphodiesterase inhibitor zaprinast.
    Silver PJ; Pagani ED; de Garavilla L; Van Aller GS; Volberg ML; Pratt PF; Buchholz RA
    Eur J Pharmacol; 1991 Jun; 199(1):141-2. PubMed ID: 1654265
    [No Abstract]   [Full Text] [Related]  

  • 6. Lack of effect of zaprinast on methacholine-induced contraction and inositol 1,4,5-trisphosphate accumulation in bovine tracheal smooth muscle.
    Chilvers ER; Giembycz MA; Challiss RA; Barnes BJ; Nahorski SR
    Br J Pharmacol; 1991 May; 103(1):1119-25. PubMed ID: 1652339
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sodium nitroprusside potentiates the depressor response to the phosphodiesterase inhibitor zaprinast in rats.
    Dundore RL; Pratt PF; Hallenbeck WD; Wassey ML; Silver PJ; Buchholz RA
    Eur J Pharmacol; 1990 Aug; 185(1):91-7. PubMed ID: 1977600
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relationship between cyclic guanosine monophosphate accumulation and relaxation of canine trachealis induced by nitrovasodilators.
    Zhou HL; Torphy TJ
    J Pharmacol Exp Ther; 1991 Sep; 258(3):972-8. PubMed ID: 1679854
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanisms of tolerance to sodium nitroprusside in rat cultured aortic smooth muscle cells.
    Papapetropoulos A; Go CY; Murad F; Catravas JD
    Br J Pharmacol; 1996 Jan; 117(1):147-55. PubMed ID: 8825356
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiovascular effects of a novel, potent and selective phosphodiesterase 5 inhibitor, DMPPO: in vitro and in vivo characterization.
    Delpy E; le Monnier de Gouville AC
    Br J Pharmacol; 1996 Jul; 118(6):1377-84. PubMed ID: 8832060
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cyclic GMP potentiation by WIN 58237, a novel cyclic nucleotide phosphodiesterase inhibitor.
    Silver PJ; Dundore RL; Bode DC; de Garavilla L; Buchholz RA; van Aller G; Hamel LT; Bacon E; Singh B; Lesher GY
    J Pharmacol Exp Ther; 1994 Dec; 271(3):1143-9. PubMed ID: 7996419
    [TBL] [Abstract][Full Text] [Related]  

  • 12. N omega-nitro-L-arginine attenuates the accumulation of aortic cyclic GMP and the hypotension produced by zaprinast.
    Dundore RL; Pratt PF; O'Connor B; Buchholz RA; Pagani ED
    Eur J Pharmacol; 1991 Jul; 200(1):83-7. PubMed ID: 1663042
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of cGMP hydrolysing phosphodiesterases 1 and 5 in cerebral artery dilatation.
    Kruuse C; Rybalkin SD; Khurana TS; Jansen-Olesen I; Olesen J; Edvinsson L
    Eur J Pharmacol; 2001 May; 420(1):55-65. PubMed ID: 11412839
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lack of cross-tolerance between nitroglycerin and endothelium-derived relaxing factor-mediated vasoactive agents in spontaneously hypertensive rats.
    De Garavilla L; Volberg ML; Pratt PF; Silver PJ; Buchholz RA
    Eur J Pharmacol; 1993 Mar; 234(1):77-82. PubMed ID: 8386094
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Zaprinast, a type V phosphodiesterase inhibitor, dilates capacitance vessels in anaesthetised rats.
    Ng SS; Pang CC
    Eur J Pharmacol; 1998 Jun; 351(3):323-8. PubMed ID: 9721024
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nicorandil: differential contribution of K+ channel opening and guanylate cyclase stimulation to its vasorelaxant effects on various endothelin-1-contracted arterial preparations. Comparison to aprikalim (RP 52891) and nitroglycerin.
    Borg C; Mondot S; Mestre M; Cavero I
    J Pharmacol Exp Ther; 1991 Nov; 259(2):526-34. PubMed ID: 1682478
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The cGMP phosphodiesterase inhibitor zaprinast enhances the effect of nitric oxide.
    Thusu KG; Morin FC; Russell JA; Steinhorn RH
    Am J Respir Crit Care Med; 1995 Nov; 152(5 Pt 1):1605-10. PubMed ID: 7582302
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the effects of the novel vasodilator FK409 with those of nitroglycerin in isolated coronary artery of the dog.
    Yamada H; Yoneyama F; Satoh K; Taira N
    Br J Pharmacol; 1991 Jul; 103(3):1713-8. PubMed ID: 1681975
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phosphodiesterase type 5 inhibition enhances vasorelaxation caused by nitroprusside in guinea pig intact heart and isolated aorta.
    Stowe F; Novalija E
    J Cardiovasc Pharmacol; 2000 Aug; 36(2):162-8. PubMed ID: 10942156
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biphasic relaxant curves to glyceryl trinitrate in rat aortic rings. Evidence for two mechanisms of action.
    Malta E
    Naunyn Schmiedebergs Arch Pharmacol; 1989; 339(1-2):236-43. PubMed ID: 2566926
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.